BeOne Medicines (BEIGF) Intangibles (2017 - 2026)

BeOne Medicines (BEIGF) has reported Intangibles for 10 consecutive years, with $61.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Intangibles fell 6.06% year-over-year to $61.0 million in Q2 2026; TTM through Jun 2026 was $61.0 million, a 6.06% decrease from a year earlier, with the FY2025 full-year figure at $62.7 million, up 22.72% from the prior year.
• Intangibles was $61.0 million for Q2 2026 at BeOne Medicines, down from $61.7 million in the prior quarter.
• Over five years, Intangibles peaked at $64.9 million in Q2 2025 and troughed at $39.7 million in Q1 2023.
• A 5-year average of $52.5 million and a median of $53.7 million in 2023 frame the typical range for Intangibles.
• Across the five-year window, Intangibles jumped 851.73% in 2022 and declined 13.26% in 2023, its largest moves.
• Over 5 years, Intangibles stood at $40.6 million in 2022, then jumped by 40.68% to $57.1 million in 2023, then fell by 10.58% to $51.1 million in 2024, then rose by 22.72% to $62.7 million in 2025, then declined by 2.79% to $61.0 million in 2026.
• The last three Intangibles figures came in at $61.0 million (Q2 2026), $61.7 million (Q1 2026), and $62.7 million (Q4 2025), per Business Quant data.